Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy

Maria Beatrice Musumeci, Vittoria Mastromarino, Matteo Casenghi, Giacomo Tini, Pietro Francia, Antonello Maruotti, Antonella Romaniello, Damiano Magrì, Rosa Lillo, Carmen Adduci, Massimo Volpe, Camillo Autore

Research output: Contribution to journalArticle

Abstract

Background Pulmonary hypertension (PH) in patients with hypertrophic cardiomyopathy (HCM) has been investigated in a small number of studies. Purpose of this study was to assess the prevalence and its association with outcome in a population of consecutive HCM outpatients. Methods We retrospectively analyzed data of 361 consecutive HCM outpatients in whom echocardiographic measurements of pulmonary artery systolic pressure (PASP) were available at initial and most recent evaluation. Four different clinical groups were specifically investigated: patients without left ventricular outflow tract obstruction (group A, 165), with obstruction (group B, 126), patients diagnosed at the age ≥ 65 (group C, 50) and patients with end stage (ES) HCM (group D, 20). Results PH was identified in 41 (11.4%) of the 361 patients at initial evaluation while it has been recognized in 25 (7,8% [1.1%/year]) during a median follow-up of 3.4 years. Analysis of subgroups showed that prevalence of PH increased from patient group A to D (8%, group A, 19%, group B, 28% group C, 70%, group D, respectively, p < 0,01). During follow-up, patients with PH showed a significant higher HCM-related mortality (p = 0.01) and morbidity (p < 0.001) as compared with those without PH, but in multivariable analysis, PH resulted an independent risk factor only for HCM-related morbidity (HR = 2.50, 95% CI 1.08–5.79, p = 0.03). Conclusion PH affects a significant proportion of patients with HCM. Its prevalence varies according to different clinical profiles. It is associated with an unfavorable clinical outcome and is an independent predictor of morbidity.

Original languageEnglish
Pages (from-to)326-332
Number of pages7
JournalInternational Journal of Cardiology
Volume248
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Hypertrophic Cardiomyopathy
Pulmonary Hypertension
Morbidity
Outpatients
Ventricular Outflow Obstruction
Pulmonary Artery
Age Groups
Blood Pressure
Mortality
Population

Keywords

  • Hypertrophic cardiomyopathy
  • Prognosis
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Musumeci, M. B., Mastromarino, V., Casenghi, M., Tini, G., Francia, P., Maruotti, A., ... Autore, C. (2017). Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. International Journal of Cardiology, 248, 326-332. https://doi.org/10.1016/j.ijcard.2017.07.010

Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. / Musumeci, Maria Beatrice; Mastromarino, Vittoria; Casenghi, Matteo; Tini, Giacomo; Francia, Pietro; Maruotti, Antonello; Romaniello, Antonella; Magrì, Damiano; Lillo, Rosa; Adduci, Carmen; Volpe, Massimo; Autore, Camillo.

In: International Journal of Cardiology, Vol. 248, 01.12.2017, p. 326-332.

Research output: Contribution to journalArticle

Musumeci, MB, Mastromarino, V, Casenghi, M, Tini, G, Francia, P, Maruotti, A, Romaniello, A, Magrì, D, Lillo, R, Adduci, C, Volpe, M & Autore, C 2017, 'Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy', International Journal of Cardiology, vol. 248, pp. 326-332. https://doi.org/10.1016/j.ijcard.2017.07.010
Musumeci MB, Mastromarino V, Casenghi M, Tini G, Francia P, Maruotti A et al. Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. International Journal of Cardiology. 2017 Dec 1;248:326-332. https://doi.org/10.1016/j.ijcard.2017.07.010
Musumeci, Maria Beatrice ; Mastromarino, Vittoria ; Casenghi, Matteo ; Tini, Giacomo ; Francia, Pietro ; Maruotti, Antonello ; Romaniello, Antonella ; Magrì, Damiano ; Lillo, Rosa ; Adduci, Carmen ; Volpe, Massimo ; Autore, Camillo. / Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. In: International Journal of Cardiology. 2017 ; Vol. 248. pp. 326-332.
@article{476a1d85cbf043fb9e85e74e02d1e5ad,
title = "Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy",
abstract = "Background Pulmonary hypertension (PH) in patients with hypertrophic cardiomyopathy (HCM) has been investigated in a small number of studies. Purpose of this study was to assess the prevalence and its association with outcome in a population of consecutive HCM outpatients. Methods We retrospectively analyzed data of 361 consecutive HCM outpatients in whom echocardiographic measurements of pulmonary artery systolic pressure (PASP) were available at initial and most recent evaluation. Four different clinical groups were specifically investigated: patients without left ventricular outflow tract obstruction (group A, 165), with obstruction (group B, 126), patients diagnosed at the age ≥ 65 (group C, 50) and patients with end stage (ES) HCM (group D, 20). Results PH was identified in 41 (11.4{\%}) of the 361 patients at initial evaluation while it has been recognized in 25 (7,8{\%} [1.1{\%}/year]) during a median follow-up of 3.4 years. Analysis of subgroups showed that prevalence of PH increased from patient group A to D (8{\%}, group A, 19{\%}, group B, 28{\%} group C, 70{\%}, group D, respectively, p < 0,01). During follow-up, patients with PH showed a significant higher HCM-related mortality (p = 0.01) and morbidity (p < 0.001) as compared with those without PH, but in multivariable analysis, PH resulted an independent risk factor only for HCM-related morbidity (HR = 2.50, 95{\%} CI 1.08–5.79, p = 0.03). Conclusion PH affects a significant proportion of patients with HCM. Its prevalence varies according to different clinical profiles. It is associated with an unfavorable clinical outcome and is an independent predictor of morbidity.",
keywords = "Hypertrophic cardiomyopathy, Prognosis, Pulmonary hypertension",
author = "Musumeci, {Maria Beatrice} and Vittoria Mastromarino and Matteo Casenghi and Giacomo Tini and Pietro Francia and Antonello Maruotti and Antonella Romaniello and Damiano Magr{\`i} and Rosa Lillo and Carmen Adduci and Massimo Volpe and Camillo Autore",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.ijcard.2017.07.010",
language = "English",
volume = "248",
pages = "326--332",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy

AU - Musumeci, Maria Beatrice

AU - Mastromarino, Vittoria

AU - Casenghi, Matteo

AU - Tini, Giacomo

AU - Francia, Pietro

AU - Maruotti, Antonello

AU - Romaniello, Antonella

AU - Magrì, Damiano

AU - Lillo, Rosa

AU - Adduci, Carmen

AU - Volpe, Massimo

AU - Autore, Camillo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background Pulmonary hypertension (PH) in patients with hypertrophic cardiomyopathy (HCM) has been investigated in a small number of studies. Purpose of this study was to assess the prevalence and its association with outcome in a population of consecutive HCM outpatients. Methods We retrospectively analyzed data of 361 consecutive HCM outpatients in whom echocardiographic measurements of pulmonary artery systolic pressure (PASP) were available at initial and most recent evaluation. Four different clinical groups were specifically investigated: patients without left ventricular outflow tract obstruction (group A, 165), with obstruction (group B, 126), patients diagnosed at the age ≥ 65 (group C, 50) and patients with end stage (ES) HCM (group D, 20). Results PH was identified in 41 (11.4%) of the 361 patients at initial evaluation while it has been recognized in 25 (7,8% [1.1%/year]) during a median follow-up of 3.4 years. Analysis of subgroups showed that prevalence of PH increased from patient group A to D (8%, group A, 19%, group B, 28% group C, 70%, group D, respectively, p < 0,01). During follow-up, patients with PH showed a significant higher HCM-related mortality (p = 0.01) and morbidity (p < 0.001) as compared with those without PH, but in multivariable analysis, PH resulted an independent risk factor only for HCM-related morbidity (HR = 2.50, 95% CI 1.08–5.79, p = 0.03). Conclusion PH affects a significant proportion of patients with HCM. Its prevalence varies according to different clinical profiles. It is associated with an unfavorable clinical outcome and is an independent predictor of morbidity.

AB - Background Pulmonary hypertension (PH) in patients with hypertrophic cardiomyopathy (HCM) has been investigated in a small number of studies. Purpose of this study was to assess the prevalence and its association with outcome in a population of consecutive HCM outpatients. Methods We retrospectively analyzed data of 361 consecutive HCM outpatients in whom echocardiographic measurements of pulmonary artery systolic pressure (PASP) were available at initial and most recent evaluation. Four different clinical groups were specifically investigated: patients without left ventricular outflow tract obstruction (group A, 165), with obstruction (group B, 126), patients diagnosed at the age ≥ 65 (group C, 50) and patients with end stage (ES) HCM (group D, 20). Results PH was identified in 41 (11.4%) of the 361 patients at initial evaluation while it has been recognized in 25 (7,8% [1.1%/year]) during a median follow-up of 3.4 years. Analysis of subgroups showed that prevalence of PH increased from patient group A to D (8%, group A, 19%, group B, 28% group C, 70%, group D, respectively, p < 0,01). During follow-up, patients with PH showed a significant higher HCM-related mortality (p = 0.01) and morbidity (p < 0.001) as compared with those without PH, but in multivariable analysis, PH resulted an independent risk factor only for HCM-related morbidity (HR = 2.50, 95% CI 1.08–5.79, p = 0.03). Conclusion PH affects a significant proportion of patients with HCM. Its prevalence varies according to different clinical profiles. It is associated with an unfavorable clinical outcome and is an independent predictor of morbidity.

KW - Hypertrophic cardiomyopathy

KW - Prognosis

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85024484088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024484088&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.07.010

DO - 10.1016/j.ijcard.2017.07.010

M3 - Article

AN - SCOPUS:85024484088

VL - 248

SP - 326

EP - 332

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -